TPG Biotech to Fund Development of JCR Pharmaceuticals Drug Candidates
TOKYO--(BUSINESS WIRE)--TPG Biotech and JCR Pharmaceuticals Co., Ltd. of Ashiya, Japan jointly announced that they have entered into an Investment Agreement to fund the late-stage clinical development of two promising drug candidates for JCR, JR-013 and Growject®. Terms of the agreement were not disclosed.